Login to Your Account



AAN 2017

Tough forms of MS may yield to new approaches

By Anette Breindl
Senior Science Editor

Thursday, April 20, 2017

The approval of Roche Holding AG's Ocrevus (ocrelizumab) last month made it the first FDA-approved multiple sclerosis (MS) drug that provided benefit to patients with primary progressive MS. (See BioWorld Today, March 30, 2017.)

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription